Hava Üsküdar Teke

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis?

Döndü Üsküdar Cansu, Hava Üsküdar Teke, Erdal Bodakçı et al. · Clinical Rheumatology · 2018 · 29 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +7

Can we predict thrombotic tendency in rheumatoid arthritis? A thromboelastographic analysis (with ROTEM)

S. M. Türk, Döndü Üsküdar Cansu, Hava Üsküdar Teke et al. · Clinical Rheumatology · 2018 · 26 citations

Rheumatoid Disorder, Rheumatology, Thrombosis +10

Regulatory T cells in Behçet’s disease: Is there a correlation with disease activity? Does regulatory T cell type matter?

Eren Gündüz, Hava Üsküdar Teke, Nazife Şule Yaşar Bilge et al. · Rheumatology International · 2013 · 20 citations

Inflammation, Allergy, T-regulatory Cell +11

Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient

Eren Gündüz, Olga Meltem Akay, Deniz Şahin et al. · Platelets · 2013 · 19 citations

Heart Failure, Pharmacotherapy, Intracardiac Thrombosis +21